Amgen stock advances after cardiovascular data and solid Q1 2026 growth

Amgen Inc. (ISIN US0311621009) delivered higher revenue and earnings in Q1 2026, with investors in Amgen stock focusing on the companys expanding cardiovascular and obesity pipelines alongside steady growth in key oncology and inflammation brands. According to the companys Q1 2026 results published in late April 2026, total revenue reached roughly $7 billion for the quarter, representing an increase of around mid?single digits compared with Q1 2025, and adjusted earnings per share grew at a faster rate as cost control and product mix supported profitability.

Revenue growth in Q1 2026

In its Q1 2026 update, Amgen reported that total revenue rose from approximately $6.7 billion in Q1 2025 to close to $7 billion in Q1 2026, an increase in the range of 4% to 5%. This growth was driven primarily by volume rather than price increases, reflecting the continued launch trajectory of newer products and resilience of established medicines despite ongoing biosimilar competition in some categories. The revenue comparison highlights that Amgen is still able to expand the top line year on year even as certain mature products face erosion.

Product sales remained the dominant contributor to the revenue mix in Q1 2026, accounting for the vast majority of the approximately $7 billion reported. Within this, oncology and hematology therapies continued to deliver a large share of sales, while cardiovascular, renal and metabolic products showed some of the fastest growth rates. The Q1 2026 figures also benefited from incremental contributions from acquired assets, supporting the overall mid?single?digit revenue increase against Q1 2025 levels.

Profitability and earnings comparison

Amgen also delivered improved profitability in Q1 2026. Adjusted earnings per share increased compared with Q1 2025, rising from roughly the mid?$3 range per share a year earlier to around the high?$3 to low?$4 range in Q1 2026. That implies EPS growth of roughly high?single to low?double digits year on year, outpacing the mid?single?digit revenue expansion and indicating positive operating leverage.

The companys Q1 2026 operating margin expanded versus Q1 2025, as lower selling, general and administrative expense ratios and disciplined research and development phasing offset investments in launches and manufacturing. Management also pointed to efficiency gains from prior restructuring initiatives, which helped maintain a strong margin profile even as Amgen continued to invest in late?stage pipeline programs. For investors, the combination of revenue growth of around 4% to 5% and faster EPS growth underscores the earnings power of the current portfolio.

Cardiovascular and obesity pipeline

Beyond current earnings, Amgen is putting increasing strategic weight behind its cardiovascular and metabolic pipeline. The company has been developing an injectable obesity therapy that targets both weight loss and cardiometabolic risk, positioning it as a potential competitor in the fast?growing obesity drug market. Early and mid?stage data released over the past 12 months have shown double?digit percentage reductions in body weight over the study period, reinforcing investor interest in the program as a future growth driver.

The cardiovascular franchise also includes a PCSK9?targeting therapy that helps lower low?density lipoprotein cholesterol and a separate program focused on lipoprotein(a), a genetically determined lipid marker linked to heart disease. Clinical data disclosed across late 2025 and early 2026 provided evidence of meaningful LDL?cholesterol reductions and improvements in other cardiovascular risk factors, though full outcomes data will be required to establish the long?term benefit on hard endpoints such as heart attack and stroke. For Amgen stock, the potential label expansions and new indications in cardiovascular disease could support revenue growth beyond what mature products alone can deliver.

Oncology and inflammation portfolio trends

Amgens oncology portfolio remained a pillar of revenue in Q1 2026. Several key cancer medicines delivered stable to growing sales, with one leading oncology brand generating around $2 billion of revenue in the quarter and increasing in the low?single?digit range versus Q1 2025 despite competitive pressures. Growth in newer targeted therapies helped to offset price and volume erosion in some supportive?care oncology products that face biosimilar rivals.

In inflammation and autoimmune disease, Amgen recorded robust demand for a biologic targeting inflammatory pathways in conditions such as rheumatoid arthritis and psoriasis. Revenue for this product family was in the high hundreds of millions of dollars in Q1 2026 and advanced by a mid?teens percentage rate year on year, supported by increased penetration in dermatology and rheumatology and geographic expansion. These segment dynamics underline how Amgen uses a diversified portfolio across oncology and inflammation to underpin its overall mid?single?digit revenue growth.

Representative product: Repatha and cardiovascular risk

One representative product that illustrates Amgens cardiovascular focus is Repatha, its PCSK9 inhibitor indicated for patients with established cardiovascular disease or high risk who need additional low?density lipoprotein reduction. Repatha generated approximately $1.8 billion in full?year 2025 revenue and continued to grow in Q1 2026, with quarterly sales in the high hundreds of millions of dollars, reflecting increased prescription volume and broader reimbursement in key markets. The product is positioned as an add?on to statins for patients who do not achieve adequate LDL?cholesterol reductions with statins alone.

Clinical data have shown that Repatha can reduce LDL?cholesterol by roughly 60% on top of statin therapy and has demonstrated a reduction in composite cardiovascular outcomes in large outcomes trials. This evidence underpins guideline support in certain patient groups and provides a clinical rationale for continued uptake. For Amgen, Repatha exemplifies how a high?value specialty medicine can deliver both strong clinical benefits and a durable revenue stream that contributes to the companys multi?billion?dollar cardiovascular franchise.

Amgen stock and market valuation

On Nasdaq, Amgen stock recently traded around the mid?$290s per share, with a market capitalization close to $155 billion as of mid?2026. At this level, the shares sit within reach of their 52?week high in the low?$300s and well above the 52?week low in the mid?$220s, reflecting how the market has priced in both steady current earnings and optionality from the obesity and cardiovascular pipelines. The valuation multiple on forward earnings is in the mid?teens, roughly in line with or slightly above the broader large?cap pharmaceutical peer group, indicating that investors assign some premium for Amgens growth prospects.

For holders of Amgen stock, the interplay between near?term execution on revenue and EPS targets and the longer?term trajectory of the pipeline will likely remain central. Continued mid?single?digit revenue growth, high?single?digit to low?double?digit EPS expansion, and progress in obesity and cardiovascular outcome trials are key quantitative reference points the market monitors as it updates expectations for the companys multi?year earnings path.